Centre Humanitaire Des Métiers De La Pharmacie company information, Employees & Contact Information

ADI - EMA’s CHMP recommends against granting marketing authorisation for donanemab Alzheimer's Disease International (ADI)

CHMP adopts a positive opinion for Emtricitabine/Rilpivirine/Tenofovir Alafenamide Viatris European AIDS Treatment Group

CHMP Provides Positive Opinion for MRD Negativity as an End Point for Regulatory Myeloma Clinical Trials OncLive

The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer’s Disease Biogen

Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors Yahoo Finance

ViiV Healthcare announces CHMP positive opinion for Vocabria + Rekambys, the first and only complete long-acting HIV treatment, for adolescents in Europe European AIDS Treatment Group

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2024 European Medicines Agency

Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease Biogen

Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer PR Newswire

ADI - EMA’s advisory committee (CHMP) recommends not granting marketing authorization for lecanemab Alzheimer's Disease International (ADI)

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 June 2025 European Medicines Agency

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2024 European Medicines Agency

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 July 2025 European Medicines Agency

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 May 2025 European Medicines Agency

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 March 2025 European Medicines Agency

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024 European Medicines Agency

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 January 2025 European Medicines Agency

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 November 2024 European Medicines Agency

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2025 European Medicines Agency

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 September 2025 European Medicines Agency

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 February 2025 European Medicines Agency

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 2024 European Medicines Agency

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27 - 30 March 2023 European Medicines Agency

GSK receives positive CHMP opinion recommending momelotinib for myelofibrosis patients with anaemia GSK

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024 European Medicines Agency

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 March 2024 European Medicines Agency

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 October 2024 European Medicines Agency

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 2022 European Medicines Agency

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20 - 23 February 2023 European Medicines Agency

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2024 European Medicines Agency

CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease Biogen

Comparative Analysis of Triglycerides From Different Regions and Mature Lactation Periods in Chinese Human Milk Project (CHMP) Study Frontiers

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 June 2023 European Medicines Agency

EMA’s CHMP Rejects Another Drug Approved by US FDA Regulatory Affairs Professionals Society | RAPS

EMA’s CHMP Adopts Updated Guideline on Manufacture of Finished Dosage Form Regulatory Affairs Professionals Society | RAPS

EMA’s CHMP Offers Negative Opinion for Sickle Cell Drug Approved by US FDA Regulatory Affairs Professionals Society | RAPS

ADI - EMA refuses marketing authorisation application for Aduhelm Alzheimer's Disease International (ADI)

AAA receives positive CHMP opinion for LysaKare EurekAlert!

EMA’s CHMP Rejects Two Drugs Approved by US FDA in 2017 Regulatory Affairs Professionals Society | RAPS

EMA recommended 77 drugs, rejected 3 in 2023 Regulatory Affairs Professionals Society | RAPS

EMA’s CHMP Recommends Six New Medicines, Releases Outcome of Sartan Investigation Regulatory Affairs Professionals Society | RAPS

Regulatory evaluation of Glybera in Europe — two committees, one mission Nature